Package Leaflet: Information for the User
Arava 100 mg film-coated tablets
leflunomide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Arava belongs to a group of medicines called antirheumatic medicines. It contains leflunomide as the active substance.
Arava is used to treat adult patients with active rheumatoid arthritis or active psoriatic arthritis.
The symptoms of rheumatoid arthritis include joint inflammation, swelling, difficulty moving, and pain. Other symptoms that affect the whole body include loss of appetite, fever, lack of energy, and anemia (reduction in the number of red blood cells in the blood).
The symptoms of active psoriatic arthritis include joint inflammation, swelling, difficulty moving, pain, red-colored plaques, and scaly skin (skin lesions).
Do not take Arava
if you have ever had an allergic reactionto leflunomide (especially a severe skin reaction, often accompanied by fever, joint pain, red spots on the skin, or blisters, e.g., Stevens-Johnson syndrome) or to any of the other ingredients of this medicine (listed in section 6), or if you are allergic to teriflunomide (used to treat multiple sclerosis).
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Arava,
Men who wish to have children should contact their doctor, who may advise them to stop treatment with Arava and take certain medications to quickly and sufficiently eliminate Arava from their body. In this case, a blood test will be necessary to ensure that Arava has been sufficiently eliminated from their body, and then they should wait at least 3 months before trying to have children.
Occasionally, Arava may cause some blood, liver, lung, or nerve problems in the arms or legs. It may also cause some severe allergic reactions (including drug rash with eosinophilia and systemic symptoms [DRESS]), or increase the risk of serious infections. For more information on these side effects, see section 4 (Possible side effects).
DRESS initially appears with symptoms similar to those of the flu and a skin rash on the face, followed by a widespread skin rash with fever, elevated liver enzyme levels in the blood, and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.
Your doctor will perform blood testsat regular intervals, before and during treatment with Arava, to monitor blood cells and liver function. Your doctor should also check your blood pressure regularly, as Arava may cause an increase in blood pressure.
Consult your doctor if you experience chronic diarrhea of unknown origin. You may undergo additional tests to establish a differential diagnosis.
Inform your doctor if you develop a skin ulcer during treatment with Arava (see section 4).
Children and adolescents
Arava is not recommended for use in children and adolescents under 18 years of age.
Using Arava with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This includes medicines obtained without a prescription.
This is especially important if you are taking:
warfarin (used as a blood anticoagulant), as monitoring is necessary to reduce the risk of adverse effects of this medicine
If you are taking a non-steroidal anti-inflammatory medicine(NSAIDs) and/or corticosteroids, you may continue taking them after starting treatment with Arava.
Vaccinations
Consult your doctor if you need to be vaccinated. Some vaccines may not be given while you are being treated with Arava or for a certain period after stopping treatment.
Taking Arava with food, drink, and alcohol
Arava can be taken with or without food.
It is not recommended to drink alcohol during treatment with Arava. Drinking alcohol during treatment with Arava may increase the risk of liver damage.
Pregnancy and breast-feeding
Do nottake Arava if you are or think you may be pregnant. If you are pregnant or become pregnant while taking Arava, there is an increased risk of having a child with serious birth defects. Women of childbearing age must not take Arava without using reliable contraceptive methods.
Tell your doctor if you plan to become pregnant after stopping treatment with Arava, as it is necessary to ensure that there are no remaining amounts of Arava in your body before becoming pregnant. The elimination of the medicine from the body may take up to 2 years. This time period can be reduced to a few weeks by taking certain medicines that accelerate the elimination of Arava from the body. In any case, before becoming pregnant, a blood test must be performed to confirm that Arava has been sufficiently eliminated from your body, and once this test is done, you should wait at least 1 month before becoming pregnant.
For more information on laboratory tests, contact your doctor.
If you suspect that you may be pregnant during treatment with Arava or in the 2 years after treatment, you must contact your doctor immediatelyfor a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest that you start treatment with certain medicines to quickly and sufficiently eliminate Arava from your body, thereby reducing the risk to your child.
Do nottake Arava while breast-feeding, as leflunomide passes into breast milk.
Driving and using machines
Arava may make you feel dizzy, which can affect your ability to concentrate and react. If this happens, do not drive or use machines.
Arava contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The usual initial dose of Arava is 100 mg of leflunomide once a day for the first three days. After this, most people need a dose of:
Swallowthe tablet wholeand with plenty of water.
It may take about 4 weeks or even longer before you start to feel better. Some patients may even notice a new improvement after 4 or 6 months of treatment. In general, Arava should be taken for prolonged periods of time.
If you take more Arava than you should
If you take more Arava than you should, consult your doctor or any other healthcare service. If possible, take the tablets or the box with you to show the doctor.
If you forget to take Arava
If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, Arava can cause side effects, although not everybody gets them.
Tell your doctor immediatelyand stop taking Arava:
Tell your doctor immediatelyif you experience:
Common side effects(may affect up to 1 in 10 people)
Uncommon side effects(may affect up to 1 in 100 people)
Rare side effects(may affect up to 1 in 1,000 people)
Very rare side effects(may affect up to 1 in 10,000 people)
Other side effects may also occur, with a frequency that is not known, such as kidney failure, decrease in uric acid levels in the blood, pulmonary hypertension, male infertility (this effect is reversible once treatment with this medicine is stopped), cutaneous lupus (characterized by skin rash/erythema in sun-exposed areas), psoriasis (new or worsening), DRESS, and skin ulcers (open sores in the skin that can show the underlying tissues), which may occur with an unknown frequency.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of the month shown.
Store in the original package.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Arava 100 mg
Appearance of the Product and Packaging Contents
Arava 100 mg film-coated tablets are white to off-white and round.
The tablets are marked with ZBP on one side.
The tablets are packaged in blisters.
Packaging of 3 tablets is available.
Marketing Authorization Holder
Sanofi-Aventis Deutschland GmbH
D-65926 Frankfurt am Main
Germany
Manufacturer
Opella Healthcare International SAS
56, Route de Choisy
60200 Compiègne
France
You can request more information about this medication by contacting the local representative of the marketing authorization holder.
Belgium/Belgique/Belgien Sanofi Belgium Tel: +32 (0)2 710 54 00 | Lithuania Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Swixx Biopharma EOOD Tel: +359 (0)2 4942 480 | Luxembourg/Luxemburg Sanofi Belgium Tel: +32 (0)2 710 54 00 (Belgium/Belgien) |
Czech Republic sanofi-aventis, s.r.o. Tel: +420 233 086 111 | Hungary SANOFI-AVENTIS Zrt. Tel: +36 1 505 0050 |
Denmark Sanofi A/S Tlf: +45 45 16 70 00 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Germany Sanofi-Aventis Deutschland GmbH Tel: 0800 52 52 010 Tel. from abroad: +49 69 305 21 131 | Netherlands Genzyme Europe B.V. Tel: +31 20 245 4000 |
Estonia Swixx Biopharma OÜ Tel: +372 640 10 30 | Norway sanofi-aventis Norge AS Tlf: +47 67 10 71 00 |
Greece sanofi-aventis AEBE Tel: +30 210 900 16 00 | Austria sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
Spain sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Poland sanofi-aventis Sp. z o.o. Tel: +48 22 280 00 00 |
France sanofi-aventis france Tel: 0 800 222 555 Call from abroad: +33 1 57 63 23 23 | Portugal Sanofi - Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 |
Croatia Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | Romania Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenia Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovak Republic Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italy Sanofi S.r.l. Tel: 800 536389 | Finland Sanofi Oy Tel: +358 (0) 201 200 300 |
Cyprus C.A. Papaellinas Ltd. Tel: +357 22 741741 | Sweden Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvia Swixx Biopharma SIA Tel: +371 6 616 47 50 | United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Date of the Last Revision of this Leaflet:
Other Sources of Information
Detailed information about this medication is available on the European Medicines Agency website http://www.ema.europa.eu/.